secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enveric Biosciences, Inc. (ENVB)
CIK:        0000890821
Form:       8-K
Filed at:   2024-01-03T23:59:59+00:00
Accession:  0001493152-24-000193
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enveric corrects EB-003 binding affinity data, shows 1000x greater potency than previously reported
--------------------------------------------------------------------------------

- EB-003 exhibits 5-HT2A partial agonism with Ki of 0.2 µM (corrected from 0.2 mM) – 1000x higher binding affinity.
- EB-003 binds 5-HT1A receptor with Ki of 3.3 µM (corrected from 3.3 mM).
- Enveric to initiate preclinical IND-enabling activities in early 2024 for EB-003.
- EB-003 selected as lead candidate from EVM301 Series; designed to promote neuroplasticity without hallucinations.
- Company used PsyAI platform to screen 51 analogs; EB-003 showed no significant head-twitch response in mice.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/890821/000149315224000193/0001493152-24-000193-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/890821/000149315224000193/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-000193

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer